I

n its latest bid to address the opioid epidemic, the Food and Drug Administration released a so-called final guidance document that is designed to help drug makers develop generic versions of abuse-deterrent painkillers.

By encouraging production of such medicines, the agency hopes to mitigate the extent to which individuals misuse opioids while simultaneously lowering prescription drug costs, a wider goal that FDA officials have adopted in recent months.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.